Results from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Although much progress has been made in treating retinal vein occlusions, much still needs to be done. Julia Haller, MD, described the four-step, evidence-based approach that she uses to treat these patients
The advent of anti-vascular endothelial growth factor (VEGF) therapy has been a tremendous advance for the treatment of retinal vein occlusion (RVO), but many other opportunities exist, said Joan W. Miller, MD.
Based on findings from a series of clinical trials in recent years, pharmacotherapy has supplanted both laser photocoagulation and a watchful waiting approach as the first-line therapy for retinal vein occlusion.
Kala Pharmaceuticals has initiated a phase II clinical trial to evaluate a nanopartical platform in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME).
Though the scenic backdrop of the Pacific Northwest at this year’s meeting of the Association for Research in Vision and Ophthalmology (ARVO) may have been different from the traditional Floridian seascape, the meeting’s world-class science continues to be at the forefront.